Table 2.
Patient data during follow-up (see also text)
| LV-DCM pts number (sex) | Further diagnoses ROSS/NYHA FC (I–IV) | BW (kg) (percentile) | Age (mo) | HR (/min) at rest | LV-EDD (mm) z-score | LV-EF (%) | RPA/LPA MVP-7 or -9 dP (mmHG) | Anti-cong. Anti. aggreg. therapy B-L-S + ASA, C | Remarks in term of FU |
|---|---|---|---|---|---|---|---|---|---|
| 1. (f) |
Improved, FR,
FC-I |
20
(98) |
42 | 87 |
40
(+1.4) |
48 | MVP-9/-9 30/45 |
B-L-S + ASA + C ++ |
RPA-PFR exchange 4 mo. after ePAB |
| 2. (f) |
Improved
FR FC-I |
6.5
(55) |
7 | 112 |
27
(+1.5) |
57 | MVP-9/-7 30/32 |
B-L-S + ASA + C | 6 mo FU Infect/RPA thrombus? RPA-PFR partial-de-banding |
| 3. (m) |
Improved
FR FC-I |
4.5
(30) |
4 | 118 |
24
(+1.5) |
55 | MVP-7/-7 32/36 |
B-L-S + ASA + C | Barth-S. related intermittent diarrhea |
Abbreviations: Anti-cong., congestive; Anti-aggreg., aggregative; ASA, acetyl-salicylic-acid; B, bisoprolol; BW, body weight; C, clopidogrel; CV, controlled ventilation; DCM, dilated cardiomyopathy; EDD, enddiastolic diameter; EF, ejection fraction; ePAB, endo-pulmonary artery banding; FC, functional class; FC-I, functional class I; FR, functional Ross-class; FU, follow-up; HR, heart rate; L, lisinopril; Le, levosimendan; LPA, left pulmonary artery; LV, left ventricle; M, milrinone; mo., months; MVP, Medtronic® Vascular Plug; pts, patients; PFR, pulmonary flow restrictor; RPA, right pulmonary artery; S, spironolactone; -S., syndrome.